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Abstract
Background: Many medicines are dosed to achieve a particular therapeutic range, and monitored using therapeutic
drug monitoring (TDM). The evidence base for a therapeutic range can be evaluated using systematic reviews, to
ensure it continues to reflect current indications, doses, routes and formulations, as well as updated adverse effect data.
There is no consensus on the optimal methodology for systematic reviews of therapeutic ranges.
Methods: An overview of systematic reviews of therapeutic ranges was undertaken. The following databases were
used: Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts and Reviews of Effects (DARE) and
MEDLINE. The published methodologies used when systematically reviewing the therapeutic range of a drug were
analyzed. Step by step recommendations to optimize such systematic reviews are proposed.
Results: Ten systematic reviews that investigated the correlation between serum concentrations and clinical outcomes
encompassing a variety of medicines and indications were assessed. There were significant variations in the
methodologies used (including the search terms used, data extraction methods, assessment of bias, and statistical
analyses undertaken). Therapeutic ranges should be population and indication specific and based on clinically relevant
outcomes. Recommendations for future systematic reviews based on these findings have been developed.
Conclusion: Evidence based therapeutic ranges have the potential to improve TDM practice. Current systematic reviews
investigating therapeutic ranges have highly variable methodologies and there is no consensus of best practice when
undertaking systematic reviews in this field. These recommendations meet a need not addressed by standard protocols.
Keywords: Systematic review methodology, Therapeutic range, Systematic review
Background
The therapeutic range of a drug is the dosage range or
blood plasma or serum concentration usually expected to
achieve the desired therapeutic effect. This does not mean
that patients may not achieve benefit at concentrations
below the minimum threshold, or may not experience ad-
verse effects if kept within the range.
In order to maintain a patient within a defined thera-
peutic range, they may be subject to therapeutic drug
monitoring (TDM). TDM involves measuring drug con-
centrations, usually in the blood, and comparing the re-
sult to a predefined window of serum concentrations
that are considered to reflect the optimum efficacy and
safety of the drug. As TDM is invasive, and will inform
important clinical decisions, it is important that target
therapeutic ranges are appropriate. If they are not, pa-
tients may not experience the full potential benefit of
the drug, or could be at risk of avoidable adverse effects.
High quality evidence of clinical efficacy and safety
should determine a drug’s therapeutic range.
The upper and lower boundaries of the therapeutic range
should be determined by the extent of harm and benefit re-
spectively. Many drugs were assigned therapeutic ranges
based on small pharmacokinetic studies performed in the
* Correspondence: D.Hawcutt@liv.ac.uk
†Equal contributors
1Institute of Translational Medicine, University of Liverpool, Liverpool,
Merseyside, UK
6National Institute for Health Research Alder Hey Clinical Research Facility,
Alder Hey Children’s Hospital, Liverpool, Merseyside, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cooney et al. BMC Medical Research Methodology  (2017) 17:84 
DOI 10.1186/s12874-017-0363-z
1960s and 1970s [1–3] or expert opinion. Most drugs are
typically assigned a single therapeutic range for all indica-
tions, at all ages, and regardless of co-medication and co-
morbidity. Following introduction of a new drug, the age
range, clinical indications, route of administration and for-
mulation may change, while the therapeutic range is not
considered. In addition, as there is a lack of empirical evi-
dence investigating the precise serum concentrations for
which a drug is most effective, reference values may differ
between laboratories. This is demonstrated in carbamaze-
pine guidelines, with quoted lower limit ranges from 4 to
8 mg/l, whilst its upper limit ranges from 8 to 12 mg/l [4].
A systematic review is the most robust method for
evaluating and synthesizing existing literature on the
beneficial and adverse effects of healthcare interventions.
Whilst the methods are well established for studies of effi-
cacy and increasingly so, for harm [5, 6], we were not
aware of a consensus on the optimum methodology for a
systematic review that aims to determine upper and lower
limits of the therapeutic range for a particular drug. Such
systematic reviews of therapeutic ranges are an emerging
and uncertain field, but potentially more important with
the advent of stratified medicine and individualised treat-
ment due to increased understanding of interindividual
variability in drug response. In this study, we have under-
taken a systematic review of those systematic reviews in-
vestigating the optimum therapeutic range of a drug, and
detailed the methodology used. From lessons learnt and
good practice examples from these studies, we propose
step-by-step recommendations for designing, analysing
and presenting systematic reviews of therapeutic ranges.
Methods
We performed a systematic overview of reviews investigat-
ing either therapeutic ranges, or those that correlate serum
drug concentrations with clinically relevant outcomes.
The Cochrane Database of Systematic Reviews (CDSR)
and the Database of Abstracts and Reviews of Effects
(DARE) were searched for relevant literature via The
Cochrane Library and Centre for Reviews and Dissemin-
ation (CRD) website. In particular, DARE uses a compre-
hensive search strategy to capture relevant systematic
reviews from other databases including MEDLINE and
EMBASE, unpublished studies and was updated regularly
until the 31st March 2015. This search was supplemented
by directly searching the MEDLINE database for relevant
studies. The search term ‘drug monitoring’ was used as
both a Medical Subject Heading (MeSH) and as a free text
term with OR Boolean operator. This search was per-
formed in February 2016, and repeated in October 2016.
A protocol was not published in advance.
Reviewer LC screened titles and abstracts for relevant
studies, prior to review of full texts of articles. At each
stage a sample of studies were reviewed independently
by DH with any disagreements resolved by consensus or
by arbitration with reviewer IS.
Studies were included if they were systematic reviews
investigating a correlation between the serum concentra-
tion and either the efficacy of the drug, or the frequency/
severity of adverse effects for a condition. There was no
restriction placed on the type of studies considered within
the systematic reviews (e.g. randomised controlled trials,
cohort studies, case reports, etc). In addition, there were
no restrictions on the medication used, indication(s) for
which the medication was used, the number of concurrent
medications, co-morbidities of the patients who received
the medication, age or gender of the participants. We ex-
cluded systematic reviews comparing therapeutic drug
monitoring vs clinical monitoring, narrative reviews and
cost benefit analyses as these do not generate information
that can inform a drug’s therapeutic range.
Reviewer LC extracted data from each of the included
systematic reviews. Predefined review characteristics in-
cluded the drug name, indication, and characteristics of
participants and the aim of the review. We assessed
whether a predetermined protocol was followed, how out-
comes were selected, how relevant literature was identified,
recommendations for clinical practice and the techniques
used for data synthesis. An AMSTAR assessment was per-
formed on each included systematic review to assess its
quality. This tool assesses the domains of study identifica-
tion and selection, data analysis and bias assessment [7].
These findings were used to form recommendations for
conducting a systematic review of therapeutic ranges.
Results
Characteristics of included studies
The search strategy returned 339 studies after duplicates
were removed. After screening titles and abstracts
twenty-two full text articles were assessed for eligibility.
Of these, eight studies were excluded as they did not in-
vestigate a correlation between serum drug level and
clinical outcomes and four studies were not systematic
reviews (see Fig. 1).
The ten systematic reviews were published from 2006
to 2016 and studied thiopurine metabolites (n = 3), my-
cophenolate mofetil (in post-transplant patients) (n = 2),
vancomycin trough concentrations (n = 1), amisulpride
(n = 1), aripiprazole (n = 1), olanzapine (n = 1), and ami-
nophylline (n = 1). The systematic reviews encompassed
a variety of indications including, inflammatory bowel
disease, asthma, Staphylococcous aureus infections, psy-
chiatric disorders and patients receiving kidney, cardiac
and liver transplants. All ten systematic reviews investi-
gated the effects of serum concentrations on disease ac-
tivity, while five systematic reviews also assessed the
correlation between serum levels and adverse effects
(Table 1).
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Study participants
Of the included systematic reviews, two examined paedi-
atric populations [8, 9] and four adult popuations [10–
13]. The remaining four systematic reviews imposed no
age restrictions of participants [14–17].
AMSTAR assessment
The results of the AMSTAR assessment are shown in
Table 2. The majority of systematic reviews performed a
comprehensive literature search and appropriate tech-
niques for data synthesis. A tool for assessment of quality/
risk of bias was used in only three reviews. The tools used
were i) the National Institute for Health and Care Excel-
lence (NICE) defined criteria for the assessment of case
series [9], ii) Meta Analyses Of Observational Studies in
Epidemiology (MOOSE) consensus statement [17], and
iii) Cochrane tool for the assessment of risk of bias [8].
Though these systematic reviews used standardized as-
sessment tools, the results of these assessments were not
formulated into conclusions. The remaining systematic re-
views used no standardized assessment tool for the ap-
praisal of quality or risk of bias in individual studies.
Three reviews assessed the potential of publication bias
across studies using the Egger method [12, 13, 17].
Protocols used
Of the ten included systematic reviews, one followed a
predefined protocol [17]. This systematic review followed
a generic protocol for the meta-analysis of clinical trials
[18]. None of the included reviews followed a specific
protocol for systematic reviews of therapeutic ranges.
Identifying relevant studies
All included systematic reviews involved PubMed/MED-
LINE in their search strategies, five studies searched Embase
[10, 11, 14–16]. Other literature searches included Google
Scholar and DirectScience [17], clinical trials registers [11]
and the UK national health system database [9]. Two sys-
tematic reviews included a grey literature search via the
Cochrane Register of Controlled Trials (CENTRAL) [8, 11].
Included studies
All included reviews analysed more than one study de-
sign. Six systematic reviews placed no restrictions on the
included study design [10, 12, 14–17], one systematic re-
view included observational data only [13], and two sys-
tematic reviews limited studies to randomised controlled
trials, cohort studies and case control studies [9, 11].
Search terms
Five systematic reviews included the search terms ‘drug
monitoring’, [9, 14–17]. Acronyms such as TDM [10]
and AUC/MIC [13] were also used. Other terms in-
cluded “Blood AND monitoring”, “physiologic monitor-
ing”, [9] or “plasma levels” [10]. One systematic review
did not outline the exact search terms used in the meth-
odology [11], and two reviews used no terms specifically
relating to therapeutic drug monitoring [8, 12].
Data extraction
For comparing serum drug levels achieved in each system-
atic review, four reviews extracted an arbitrary threshold
level, and measured the beneficial effects of the drug above
Fig. 1 Search results. DARE - Database of Abstracts of Reviews of Effects, SR – Systematic review
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Table 1 Included studies
Author Drug Indication Protocol Number of
studies
Adverse
effects
Study design “drug
monitoring”
included in
search
Information sources RoB/Quality assessment of
studies
Meta analysis
Cooney
2016 [8]
Aminophylline Asthma No 12 Yes No
restrictions
No Medine, CINAHL, Cochrane
Central, and Web of Science
Cochrane tool for
assessment of risk of bias
[35], CASP tool [36]
No
Sparshatt
2009 [10]
Amisulpride Schizophrenia/
schizoaffective disorder
No 10 Yes No
restrictions
No Embase, Medline and PubMed None No
Sparshatt
2010 [14]
Aripirazole No specific diagnosis No 8 No No
restrictions
Yes Embase, Medline, and PubMed None No
Knight
2008 [11]
Mycophenolate
Mofetil
Transplant patients No 12 Yes RCTs,
Observational
studies
No Medline, Embase, Cochrane
Central, Transplant Library,
Clinical trial registries
None No
Zuk 2009
[15]
Mycophenolate
Mofetil
Heart transplant No 7 No No
restrictions
Yes Medline Embase None No
Bishara
2013 [16]
Olanzapine Schizophrenia/
schizoaffective
disorder/bipolar
disorder
No 30 Yes No
restrictions
Yes PubMed, Medline, Embase None Yes
Konidari
2014 [9]
Thiopurine IBD No 15 Yes RCTs,
Observational
studies
Yes PubMed, Medline, UK national
health system database
NICE defined criteria for
quality assessment of case
series [37]
No
Moreau
2014 [17]
Thiopurine IBD Yes 17 No No
restrictions
Yes Medline, Cochrane Library,
DirectScience, and Google
Scholar
Nonea Yes
Osterman
2006 [12]
Thiopurine IBD No 12 No No
restrictions
No Medline, PubMed Plus None Yes
Prybylski
2015 [13]
Vancomycin S. aureus bacteraemia No 14 No Observational
studies
No PubMed None Yes
RoB Risk Of bias, IBD Inflammatory Bowel Disease, RCT Randomised controlled trial, CENTRAL Central Register of Controlled Trials
aMoreau et al. used the MOOSE consensus statement to assess reporting quality, but do not report the results of their assessment
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this threshold [9, 12, 13, 17], and two extracted the data for
area under the curve (AUC) or data on single point moni-
toring [11, 15]. The remaining reviews extracted the
mean ± standard deviation of drug level achieved across
participants [8, 10, 16]. One review extracted the timing of
drug measurement [11], and two reviews performed separ-
ate analyses depending on the type of assay used [13, 17].
Statistical analyses
Of the ten included systematic reviews, four used meta-
analyses to investigate the association between low versus
high serum drug levels and clinically relevant outcomes
(Table 3). One of these reviews assessed the relationship
between vancomycin trough levels and treatment failure,
defined as a composite endpoint that included mortality
and persistent bacteraemia. This review used data from
several primary studies, which compared the occurrence
of treatment failure in patients with serum levels below
15 mg/l with patients above 15 mg/l. This threshold level
was chosen based on a cohort study indicating a two-fold
risk of treatment failure when vancomycin levels are
<15 mg/l in the treatment of MRSA bacteraemia [19].
This study relied on primary studies using similar thresh-
old levels [13]. Two systematic reviews investigated the re-
lationship between threshold values of tioguanine-6
(TGN-6) and clinical remission in patients with inflamma-
tory bowel disease. In one systematic review, the authors
only included studies which compared participants with
TGN-6 concentration ≥ 230 pmol/8 × 108^8 RBC with
those below, with this figure decided a priori [17]. One
Table 2 Results of AMSTAR assessment
Pryblyski
2015
Konidari
2014
Moreu
2014
Sparshatt
2009
Knight
2008
Osterman
2006
Cooney
2016
Sparshatt
2010
Zuk
2009
Bishara
2013
Was an a priori design (protocol) provided? ✗ ✗ ✓ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Was there duplicate study selection and data
extraction?
✗ ✓ ✓ ✗ ✗ ✗ ✓ ✗ ✗ ✓
Was a comprehensive literature search
performed?
✗ ✓ ✗ ✓ ✓ ✗ ✓ ✗ ✓ ✓
Was the status of publication (i.e. grey
literature) used as a criterion?
✗ ✓ ✗ ✗ ✓ ✗ ✓ ✗ ✗ ✓
Was a list of studies (included and excluded)
provided?
✗ ✓ ✓ ✗ ✗ ✗ ✓ ✓ ✗ ✓
Were the characteristics of the included
studies provided?
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗
Was the scientific quality of the included
studies assessed?
✗ ✓ ✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗
Was the scientific quality of the studies used
in formulating conclusions?
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Were the methods used to combine the
findings of the studies appropriate?a
✓ ✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✓
Was the likelihood of publication bias
assessed?b
✓ ✗ ✓ ✗ ✗ ✓ ✗ N/A N/A ✗
Was a conflict of interest included? ✗ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓
aMethods used to combine the findings of studies were deemed inappropriate if no a priori statistical techniques were outlined in the methodology
bAMSTAR methodology states systematic reviews with <10 studies included do not to assess publication bias (marked N/A)
Table 3 Meta analyses performed
Study Intervention Comparator Outcome
Pryblyski
2015 [13]
Vancomycin serum levels >15 mg/l Vancomycin serum levels <15 mg/l Mortality, persistent
bacteraemia
Moreau
2014 [17]
Patients with serum TGN concentrations above
230 pmol/ pmol/8.10^8
Patients with serum TGN concentrations below
pmol/8.10^8
Clinical remission of
inflammatory bowel disease
Osterman
2006 [12]
Patients with serum TGN concentrations above
predetermined threshold
Patients with serum TGN concentrations below
predetermined threshold
Clinical remission of
inflammatory bowel disease
Osterman
2006 [12]
Patients with active disease Patients in clinical remission Serum TGN levels
Bishara
2013 [16]
High serum olanzapine concentrations Low serum olanzapine concentrations PANSS
TGN tioguanine-6, PANSS Positive and negative symptom scale
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study performed a similar analysis, but included studies
with different threshold levels in the same meta analysis
(either 235 pmol/8 × 108 or 250 pmol/8 × 108) [12]. The
fourth systematic review planned a meta analysis investi-
gating the relationship between high and low olanzapine
serum concentrations on symptom scores in patients with
schizoaffective disorder, however there was insufficient
data reported to enable meta analysis [16].
Six systematic reviews did not perform quantitative data
synthesis, and instead data analysis was done descriptively.
Four reviews planned no meta analysis a priori in their
methodologies, it is not clear in these studies why quanti-
tative data synthesis was not performed [9–11, 15]. One
review performed a meta analysis correlating dosage to
clinical outcomes, but had insufficient data for a similar
analysis correlating plasma concentrations of aripirazole
to clinical outcomes [14]. One systematic review planned
a meta analysis a priori, but this was deemed inappropri-
ate by the investigators following data extraction due to
the heterogeneity of data due to variability in the thresh-
old of drug levels used, and inconsistencies in reporting of
drug levels achieved across participants [8].
Clinical relevance
No included systematic reviews were able to provide a de-
finitive therapeutic range from systematically reviewed evi-
dence. Though a relationship between serum concentration
and clinical efficacy was found in three reviews [10–12],
this was not translated into definable upper and lower
limits of drug concentrations that conferred maximum effi-
cacy and safety. This is because a definable cut off point
reflecting efficacy and safety could not be established at the
lower and upper limits respectively. One systematic review
found that the established therapeutic range was able to
predict toxicity but unable to predict clinical benefit in pa-
tients receiving thiopurine for IBD [9], and three reviews
found a weak association between serum drug concentra-
tions and clinical outcomes [8, 11, 13].
Discussion
Published systematic reviews correlating serum concen-
trations of a drug with clinical outcomes are scarce.
There were none identified that were able to compare
RCTs of different therapeutic ranges, and hence other
study designs were used in data synthesis.
A strength of review is that it has identified methodo-
logical variations, as well as considerable inconsistencies, in
the reporting of existing published systematic reviews of
therapeutic ranges. There is clearly a need to improve or
standardize methods. A limitation of this review is that it
only identifies drugs in which the therapeutic range has
been systematically reviewed. There are classes of drugs
where there is considerable evidence supporting the
therapeutic ranges but no systematic reviews have been
undertaken (for example, aminoglycoside antibiotics).
We have developed recommendations for future reviewers
examining therapeutic ranges based on these findings.
Determining the scope and question of the review
Most of our included systematic reviews investigated the ef-
fect of serum concentrations of a particular drug, for a par-
ticular indication, in a particular population. Similar to
typical systematic reviews, the research question should be
specified a priori. The reviewers should report whether
their review is focussed on the lower limit of the thera-
peutic range, the upper limit, or both; and the population,
indication, chronicity and route of the drug. It is important
to consider these when deciding the review question as
drugs may be used for more than one indication, and in
groups of patients with differing characteristics. If the medi-
cine has more than one indication, an appropriate range for
each use should be explored as the optimal therapeutic
range may vary with age, population and indication. For ex-
ample, the plasma salicyclate range for the treatment of in-
flammatory conditions is considerably greater than that
required for analgesia [20].
Outcomes
Selected outcomes must reflect beneficial and harmful ef-
fects of the drug that are relevant to clinical practice, in
context of the population of interest. For example, focus-
sing on surrogate physiological outcomes such as improve-
ments in Forced Expiratory Volume in One Second (FEV1)
in asthma [21] and electroencephalogram (EEG) measure-
ments in epilepsy [3] may not reflect whether the drug has
a beneficial clinical effect at a given concentration.
It is unclear how review outcomes were selected in most
systematic reviews. One way of identifying important out-
comes is to see whether there is an established core out-
come set, which should be measured and reported in all
clinical trials in a given condition [22]. The Core Outcome
Measures in Effectiveness Trials (COMET) Initiative con-
tains a database of existing core outcome sets [23], how-
ever this does not comprehensively cover all possible
harmful effects of drugs. A framework of outcomes has
been developed [24], which may help decide which are
most important and relevant for the particular topic under
review. In some situations, patients have been involved in
identifying which outcomes are directly relevant to them
[25], and if such studies are available they should be con-
sidered when identifying appropriate outcomes for a sys-
tematic review.
With regards to adverse effects of drugs, at particular
serum concentrations, it is important to consider whether
the scope of the review should be broadened to include
outcomes in wider populations and across other indications
[26]. This will not only be determined by the time and
Cooney et al. BMC Medical Research Methodology  (2017) 17:84 Page 6 of 9
resources available, but also whether the pharmacological
properties of the drug, and the susceptibility of the patient
to adverse effects, varies between groups. One example
where this may be particularly relevant is in preterm neo-
nates, who are uniquely prone to long term side effects
which may not be seen in other populations, for example
cerebral palsy from steroid use [27–29], and problems with
cardiovascular adaptation to extra-uterine life from non-
steroidal anti-inflammatory drugs [30].
Included studies
Reviewers must balance the need to capture all relevant
data with the time and resources available. Many thera-
peutic ranges are under researched, and few primary stud-
ies specifically aim to investigate the therapeutic range of a
drug. Studies of most interest will be those that report both
a measure of serum drug concentration and at least one of
the selected clinical outcomes. Authors may consider the
levels of available evidence they may find prior to searching
for relevant studies. Categorising studies in this way helps
systematically grade the available evidence. This avoids pla-
cing inappropriate weight on studies that are methodologic-
ally less robust when formulating conclusions.
The most useful studies are well designed randomised
controlled trials (RCTs) comparing two or more thera-
peutic ranges for the same drug, and reporting clinically
relevant outcomes. Such studies have been conducted to
examine serum concentrations of lithium in adults with
bipolar disorder for prophylaxis of mania [31] and serum
concentrations of teicoplanin in adults who are critically
ill with gram negative infections [32].
In practice, trials directly comparing therapeutic ranges
are uncommon, and we propose that the next level of evi-
dence will incorporate either observational data or indir-
ect comparisons between clinical trials such as RCTs
comparing drug to placebo/other treatment or observa-
tional studies.
Observational data may be obtained from cohort stud-
ies, case-control studies, or case series. Indirect evidence
may be gained from identifying RCTs that have com-
pared the drug against a common comparator (likely
placebo), and then analysing whether studies in which a
higher serum concentration was achieved demonstrated
better effects on beneficial and harmful outcomes.
Search terms
Combinations of indexing terms such as Medical subject
headings (MeSH) and textwords should be used by re-
viewers to form a search strategy that maximizes sensitivity
whilst minimizing specificity whilst keeping the number of
records to sift manageable within the logistical constraints
of the review. If indirect evidence is considered for
inclusion, the search strategy must be sufficiently sensitive
to return studies that are not necessarily ‘labelled’ as
investigations into the therapeutic range of a drug (e.g.
RCTs comparing drug to placebo). As Information on
therapeutic ranges may be presented using variable termin-
ology, MeSH terms such as “Drug-Related Side Effects and
Adverse Reactions”, “Drug monitoring”, “Pharmacovigi-
lance”, “Adverse Drug Reaction Reporting Systems”, “Moni-
toring, Physiologic”, “Clinical Pharmacy Information
Systems” may lead to inclusion of relevant studies in MED-
LINE and other relevant indexing terms will be necessary
in other databases.
Quality/risk of bias assessment
An assessment of quality allows the reviewers to present
the degree to which the results in the available literature
are likely to be valid and robust, and whether conclu-
sions that impact on clinical practice should be imple-
mented. There are specific considerations when
conducting a systematic review of therapeutic ranges.
There are a large number of critical appraisal tools for
different study designs, each with varying emphasis on dif-
ferent aspects of quality, although many lack information
on how they were developed [33]. These include the Crit-
ical Appraisal Skills Programme (CASP) tools, the Graph-
ical Appraisal Tool for Epidemiology (GATE) and the Case
Reports (CARE) tool. These tools were not devised for the
appraisal of therapeutic drug monitoring studies specific-
ally, and therefore they may not address specific concerns
when assessing the quality of included studies in reviews in-
vestigating the optimum therapeutic range of a drug.
Risk of bias in RCTs can be conducted using the
Cochrane risk of bias (RoB) tool available from http://
handbook.cochrane.org/chapter_8/8_assessing_risk_of_bia-
s_in_included_studies.htm. This tool was developed for
systematic reviews investigating the efficacy of an interven-
tion, and allows a systemic and consistent approach to all
included RCTs. Though this tool allows a systemic and
consistent approach, it is limited by its inter-assessor vari-
ability, and its tendency to judge older studies as a higher
risk of bias. Risk of bias in non-randomised studies can be
assessed using the ROBINS-I tool [34].
Although a specific systematic assessment tool for TDM
studies is yet to be developed, we suggest the following
considerations to be integrated into the quality assessment
of included studies. Different assays vary in accuracy and
this can lead to misleading measurements of serum con-
centrations and reviewers should consider the appropri-
ateness of the methods for determining serum drug
concentrations in individual participants. Furthermore,
drug clearance is a dynamic process and the time period
between drug administration and serum measurement
should be consistent between participants. Selected out-
comes should adequately represent harm and benefit, and
techniques for measuring adverse effects should be de-
cided a priori as ad hoc measurement of adverse effects
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carries risk of selective outcome reporting which could
misinform the upper limit of a therapeutic range.
Statistical analysis
Data synthesis in systematic reviews of therapeutic
ranges will involve a comparison of outcomes between
participants who demonstrate differing serum levels of a
drug. Studies vary in how they summarize the serum
levels, and this will impact the approach to meta-
analysis. For example, studies may compare mean serum
levels between those responding to the drug and those
not (or experiencing an adverse event or not) (continu-
ous data), in which case a meta-analysis of differences in
means can be undertaken to provide a pooled estimate
of the difference. Alternatively, studies may compare
numbers responding and not responding to a drug (or
experiencing an adverse event or not) between those
with serum levels below and above a particular threshold
(dichotomous data). In such studies it would be com-
mon to report the relative risk or odds ratio of the event
of interest, in which case a meta-analysis of the effect
estimates can be undertaken to provide a pooled effect
estimate. In any case, it is important to assess for hetero-
geneity between studies, and utilising a random effects
approach to meta-analysis is recommended where the
heterogeneity is found to be large. Potential sources of
heterogeneity can also be explored by subgroup analyses
and, where possible, meta-regression.
It is important to note that conducting a meta-analysis
may not always be possible within a systematic review,
and should only be undertaken where there are a suffi-
cient number of studies with comparable outcomes and
exposure groups. For example, where patients are
grouped according to a drug level threshold, it may only
be appropriate to meta-analyse studies which utilize the
same, or at least similar, threshold, and some thought
would need to be given as to what range of thresholds
would be considered similar.
Where a meta-analysis is not appropriate, a descriptive
analysis should be provided of the included studies’ findings.
Interpreting the results of the review
In reviews appraising the evidence around a standard
therapeutic range used in practice, the results may have
four possible implications. The range may be appropri-
ate, the upper or lower limit should be amended in light
of the review results, or there is no evidence on which
to make any recommendations (Table 4).
The quality of the evidence around the recommenda-
tions of the review should be presented, in context of a
summary of the population, indication, and outcomes
included in the review.
Conclusion
Evidence based therapeutic ranges have the potential to
improve TDM practice. Current systematic reviews in-
vestigating therapeutic ranges have highly variable meth-
odologies and there is no consensus of best practice
when undertaking systematic reviews in this field.
Consistency in the searching, selection and appraisal of
studies is necessary if these reviews are to inform pre-
scribing practice. These recommendations meet a need
not addressed by standard protocols.
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